A few steps before ..., or how to protect a pregnant woman from iron deficiency and anemia. Literature review





iron deficiency anemia, anemia of chronic disease, iron deficiency, obstetric and perinatal complications, prevention, pregravid preparation, liposomal iron, Ferroview


The article presents modern data on the etiology, pathogenesis, diagnosis, prevention and treatment of iron deficiency anemia (IDA) and anemia of chronic disease, as well as their combination on the eve of and during pregnancy. The emphasis is made on the role of iron deficiency of any etiology in the development of obstetric and perinatal complications, especially its impact on the central nervous system formation and further psychophysical child development. Need for prevention of iron deficiency states in risk groups which includes all women of reproductive age who have menstruation is shown based on evidence-based medicine data. Effectiveness and safety of modern drugs containing iron in oral and parenteral forms has analyzed. The paper presents data on the safety and effectiveness of an innovative form of ferric iron in the form of liposomal iron, which differs in the mechanism of action, digestibility and the absence of side effects typical for this group of drugs.

According to various authors the frequency of IDA in pregnant women ranges up to 80%, in puerperas up to 40%. It is unimpossible to stop IDA without iron supplementation only with an iron-rich diet. Two main groups of iron preparations are used to correct iron deficiency differing in the valence of iron atoms – bivalent iron salts and trivalent complexes. These drugs differ in the tolerability and bioavailability of atomic iron. Liposomal iron is a new drug for treatment of iron deficiency and IDA today; it has an innovative way of iron delivery to the body. Liposomal iron has advantages for the prevention of anemia in patients with anemia of chronic disease or its combination with IDA (inflammatory bowel diseases, obesity, after resection of the stomach and intestines, etc.). An innovative form of liposomal iron in Ukraine is represented by a dietary supplement Ferroview containing 30 mg of elemental iron, that is corresponds to the average prophylactic dose recommended in WHO documents

Author Biography

І. А. Жабченко, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine", Kyiv

MD, professor, head of the Department of Pathology of Pregnancy and Childbirth


  1. Rostov Regional Clinical Hospital of the Ministry of Health of the Rostov Region (RF). Anemias: iron deficiency, B12-deficiency and anemia of chronic diseases: Information letter for hematologists, general practitioners, interns and residents. Rostov-na-Donu (2013): 20 p.
  2. Solovyova, A.V., Sturov, V.G., et al. Anemia and reproductive health. Ed. by V.E. Radzinsky. Moscow. Editorial board of StatusPraesens Journal (2019): 200 p.
  3. Bril, Y.A. “Preventive and therapeutic strategies for iron deficiency in the practice of an obstetrician-gynecologist.” StatusPraesens. Gynecology, obstetrics, sterile marriage 3.39 (2017): 79–88.
  4. Vyalov, S.S. “The effectiveness and safety of liposomal iron in the treatment of anemia after resection of the stomach or intestines.” Clinical Pharmacological Therapy 25.4 (2016): 42–6.
  5. Gopchuk, O.M. “Iron deficiency anemia.” Women's Health 9.145 (2019): 32–7.
  6. Zhabchenko, I.A. “Anemia in the postpartum period.” Works of the S.I. Georgievsky Crimean State Medical University “Problems, achievements and prospects for the development of biomedical sciences and practical health care.” 144 Part III (2008): 121–5.
  7. Logutova, L.S. “Anemia in pregnant women: issues of etiology, diagnosis and treatment.” Russian Medical Journal 5 (2016): 290–3.
  8. Medved, V.I., Kirilchuk, M.Y. “Prevention of hypertension and anemia in pregnant women.” Women’s Doctor 4.84 (2019): 28–30.
  9. Radzinsky, V.E., Knyazev, S.A., Kostin, I.N. Obstetric risk. Moscow. Eksmo (2009): 288 p.
  10. Radzinsky, V.E. “Not mystic, but the secrets of wisdom.” StatusPraesens 2.55 (2019): 7–9.
  11. Rukavitsyn, O.A. “Anemia of chronic diseases: some aspects of pathogenesis and ways of correction.” Oncohematology 11.1 (2016): 37–46.
  12. Ryabinkina, T.S., Simonovskaya, H.Y., Rudnev, O.D. Older reproductive age: contraception and not only. Rational contraception for older women: contraceptive and non-contraceptive aspects. Newsletter. Ed. by V.E. Radzinsky. Moscow. Editorial board of StatusPraesens Journal (2014): 16 p.
  13. Stuklov, N.I., Kozinets, G.I., Levakov, S.A., et al. “Anemia in gynecological and gynecological oncological diseases.” Moscow. MIA (2013): 238 p.
  14. Stuklov, N.I. “Ferrodeficiency syndromes in questions and answers.” StatusPraesens 5.42 (2017): 120–4.
  15. Stuklov, N.I., Knyazev, O.V., Parfenov, A.I., et al. “Comparative efficacy of using a new sucrosomal form of iron for oral administration and intravenous ferrotherapy in the treatment of anemia in patients with inflammatory bowel diseases.” Clinical Medicine 95.12 (2017): 1112–7.
  16. Fedorova, T.A., Borzykina, O.M., Bakuridze E.M., et al. “Correction of iron deficiency anemia in patients with gynecological diseases using liposomal iron.” Gynecology 19.1 (2017): 68–72.
  17. Shikh, E.V., Bril, Y.A. “Iron deficiency: a disaster for neurogenesis.” StatusPraesens 10 (2018): 82–8.
  18. Abu-Our, N.M., Ja, M.M. “The impact of maternal iron deficiency and iron deficiency anemia on child’s health.” Saudi Med J 36.2 (2015): 146–9.
  19. Amstad Bencaiova, G., Krafft, A., Zimmermann, R., Burkhardt, N. “Treatment of anemia of chronic disease with true iron deficiency in pregnancy.” J Pregnancy 2017 (2017): 4265091.
  20. Auerbach, M., Ballard, H. “Clinical use of intravenous iron: administration, efficacy, and safety.” Hematology Am Soc Hematol Educ Program 2010 (2010): 338.
  21. Bircher, A.J., Auerbach, M. “Hypersensitivity from intravenous iron products.” Immunol Allergy Clin N Am 34 (2014): 707.
  22. Boggs, D.R. “Fate of a ferrous sulfate prescription.” Am J Med 82 (1987): 124.
  23. Breymann, C., Xu-ming, B., Blanco-Capito, L.R., et al. “Expert recommendation for the diagnosis and treatment of iron deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region.” J Perinatal Medicine 39.2 (2011): 113–21.
  24. Cancelo-Hidalgo, M.J., Castelo-Blanco, C., Palacios, S., et al. “Tolerability of different oral iron supplements: a systematic review.” Curr Med Res Opin 29 (2013): 291.
  25. Giordano, G., Mondello, P., Tambaro, R., et al. “Intravenous iron support vs oral liposomal iron support in patients with refractory anemia treated with Epo alpha. Monocentric prospective study.” Leukemia Res 35 (2011): S137.
  26. Giordano, G., Mondello, P., Tambaro, R., et al. “Biosimilar erythropoietin alpha is effective as originator erythropoietin alpha plus liposomial iron and B12 and folates in patients with refractory anemia: A retrospective real-life approach.” Blood 124.21 (2014): 4880.
  27. Goddard, A.F., James, M.W., McIntyre, A.S., et al. “Guidelines for the management of iron deficiency anaemia.” Gut 60 (2011): 1309.
  28. World Health Organization. Daily iron supplementation in adult women and adolescent girls: Guideline. WHO. Geneva (2016).
  29. Donker, A.E., Raymakers, R.A., Vlasveld, L.T., et al. “Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or hem synthesis.” Blood 123 (2014): 3873.
  30. Khalafallah, A., Dennis, A., Bates, J., et al. “A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy.” J Intern Med 268 (2010): 286.
  31. Lozano, R., Foreman, K., et al. “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global burden of disease study 2010.” Lancet Glob Health 380 (2013): 2095–2128.
  32. Okam, M.M., Mandell, E., Hevelone, N., et al. “Comparative rates of adverse events with different formulations of intravenous iron.” Am J Hematol 87 (2012): E123.
  33. Jahre, A., Dietl, S., Cupisti, M., et al. “Pregnancy and Obstetrical Outcomes in Women Over 40 Years of Age Schwangerschaft und Geburt bei Frauen über 40.” Zollner Geburtshilfe Frauenheilkd 75.08 (2015): 827–32.
  34. Scott, S.P., Chen-Edinboro, L.P., Caulfield, L.E., Murray-Kolb, L.E. “The impact of anemia on child mortality: An updated review.” Nutrients 6.12 (2014): 5915–32.
  35. Tandu-Umba, B., Mbangma, A.M. “Association of maternal anemia with order risk factors in occurrence of Great obstetrical syndromes at university clinics, Kinshasa, DR Congo.” BMC Pregnancy Childbirth 15.183 (2015).
  36. Tarantino, G. “New delivery system for high bioavailable iron supplements.” Nutrafoods 12 (2013): 71–8.
  37. WHO and the International Bank for Reconstruction and Development. Tracking Universal Health Coverage: 2017 Global Monitoring Report. 88 p.
  38. Weiss, G., Goodnough, L.T. “Anemia of inflammation.” Blood 133.1 (2019): 40–50.
  39. World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. WHO. Geneva (2017).
  40. Siegenthaler, W. Differentialdiagnose innerer Krankheiten. Thieme Verlag. New York (1984): 4.33–4.35.



How to Cite

Жабченко, І. А. (2020). A few steps before ., or how to protect a pregnant woman from iron deficiency and anemia. Literature review. REPRODUCTIVE ENDOCRINOLOGY, (54), 46–54. https://doi.org/10.18370/2309-4117.2020.54.46-54



Pregnancy and childbirth